“US Fecal Microbiome Transplant Market Outlook 2025” Report Highlight:
*US Fecal Microbiota Transplant Market Opportunity: andgt; US$ 150 Million by 2025
* Number of Fecal Microbiota Transplant Market in US: andgt;20000 by 2025
*US To Dominate Global Fecal Microbiota Transplant Market: andgt; 50% Market Share
*Fecal Microbiota Transplant vs. Antibiotic Therapy
Download Report: https://www.kuickresearch.com/report-us-fecal-microbiome-transplant-market-outlook-2025.php
The human microbiota has major and vital role in the well-being of the human host, which contributes actively in the occurrence of a wide variety of diseases. Microorganisms have extensive influence throughout the human body and hence research on the Microbiota modifying methods such as Fecal Microbiota Transplant , are under investigation. Currently, US is emerging as global leader in fecal microbiota transplant market. The number of procedures of Fecal Microbiota Transplant is increasing continuously in US and it will continue to follow same trajectory in future driven by increasing awareness and high regulatory approvals. In 2018, the US Fecal Microbiota Transplant market was less than US$ 100 Million and is expected to double its size by 2025.
The strong clinical pipeline of Fecal Microbiota Transplant is acting as a major driving force for the exponential growth of US fecal microbiota transplant market. There are more than 250 trials under investigation from which about 36 trials are under Phase III and phase IV of clinical development. The trials are related to different diseases such as metabolic disorders, cardiovascular disorders, psychiatric disorders and cancer also. This will indicate a bright future of Fecal Microbiota Transplant market and continuous growth will take place in future years.
Fecal Microbiota Transplant is currently approved only for the management of C. difficile infection. As the Prevalence rate of C. difficile infection is increasing day by day, the number of Fecal Microbiota Transplant procedures will increase continuously. High efficacy of Fecal Microbiota Transplant as compared to the standard antibiotic therapy is also acting as a major driving force, which will promote the Fecal Microbiota Transplant market. The approval of Fecal Microbiota Transplant for management of inflammatory bowel disease will also take place within a year, which further enhances the number of Fecal Microbiota Transplant procedures in future and all this leads to rapid growth of Fecal Microbiota Transplant market.
1. What is Fecal Microbiome Transplant (FMT)
1.1 Overview
1.2 History of FMT
2. Need of Fecal Microbiota Transplantation
2.1 Therapeutic Needs
2.2 Supplementary Needs
2.3 Need for Disease Prevention
3. Clinical Trial Related To Fecal Microbiota Transplant
3.1 Clinical Trial for Recurrent C. Difficile
3.2 Clinical Trial for Inflammatory Bowel Disease (IBD)
3.3 Other FMT Related Clinical Trials
4. US – Fecal Microbiota Transplant Market Scenario
4.1 Overview
4.2 Current Market Scenario
5. Fecal Microbiota Transplant Price Analysis
5.1 FMT Preparation Formats – Availability and Cost Analysis
5.2 Additional Expenditures
6. FMT vs. Antibiotic Therapy
6.1 Efficacy Comparison
6.2 Cost Effectiveness of Antibiotic Therapeutics vs. FMT
7. US – Fecal Microbiota Transplant Market Drivers
8. Challenges for US Fecal Microbiota Transplant Market
9. US – Fecal Microbiota Transplant Market Future Outlook
10. Competitive Landscape
10.1 OpenBiome
10.2 Maat Pharma
10.3 Finch Therapeutics
10.4 Rebiotix
10.5 Seres Therapeutics
10.6 Vedanta Bioscience
Figure 1-1: Procedure of Fecal Microbiota Transplantation (FMT)
Figure 1-2: Approaches for Microbiome Therapeutics
Figure 1-3: Types of Microbiota Transplant
Figure 1-4: Microbiome Composition of Healthy Human Gut
Figure 15: Historical Development of Fecal Transplantation (300AD-1950AD)
Figure 1-6: Historical Development of FMT (After 1950)
Figure 2-1: Needs of Fecal Microbiota Transplant
Figure 2-2: Disorders with Positive Effect of FMT
Figure 3-1: Number of Clinical Trial Studies Related to Fecal Microbiota Transplant in Different Phases, 2019
Figure 3-2: Fecal Microbiota Transplant in Different Phases of Clinical Trial (%), 2019
Figure 3-3: Status of Active FMT Clinical Trials
Figure 3-4: FMT Clinical Trial in Management of C. Difficile Infection, 2019
Figure 3-5: FMT Clinical Trial in Management of Inflammatory Bowel Disease, 2019
Figure 4-1: US andndash; Total C. Difficile Patients vs. FMT Eligible C. Difficile Patients, 2019
Figure 4-2: US – Antibiotic Responsive vs. Non-Responsive C. Fifficile Patients (%), 2019
Figure 4-3: Probability of 1st, 2nd, and 3rd Episode of C. Difficile Infection Reoccurrence (%), 2019
Figure 4-4: US andndash; Number of FMT Treatments Shipped by OpenBiome, 2014 – 2019
Figure 4-5: Global Microbiome Therapeutic Market Size (US$ Million), 2018 – 2025
Figure 4-6: Microbiome Therapeutic Market Size andndash; Global vs. US (US$ Million), 2018
Figure 4-7: Global Microbiome Therapeutic Market Share (%) andndash; US, Europe and Rest of World, 2018 and 2025
Figure 4-8: US andndash; Number of FMT Procedures, 2018 – 2025
Figure 4-9: US andndash; FMT Market Size (US$ Million), 2018 – 2025
Figure 5-1: Components of Total Cost for Fecal Microbiota
Figure 5-2: US – Fecal Microbiota Transplant Preparation Formats Available in Market
Figure 5-3: US andndash; Price of OpenBiome’s Upper, Lower and Oral Delivery FMT Preparation (US$), September’2019
Figure 54: US andndash; Cost of 30 Capsules and per Unit Price of OpenBiome FMT (US$), September’2019
Figure 5-5: Additional Expenditure Associated with Fecal Microbiome Transplantation
Figure 5-6: US andndash; Average Cost of Colonoscopy, Sigmoidoscopy and Endoscopy Procedures (US$), 2018
Figure 5-7: US andndash; Average Stay Charges/ Day in Local Government, Non-Profit and Profitable Hospital (US$), 2016
Figure 6-1: Standard Antibiotics for Management of C. Difficile Infection
Figure 6-2: Patient Cure Efficacy of FMT (Colonoscopy) and Oral Vancomycin against Recurrent CDI (%)
Figure 6-3: Patient Cure Efficacy of FMT (Nasogastric), Oral Vancomycin and Vancomycin + Bowel Lavage against Recurrent CDI (%)
Figure 6-4: Treatment Duration of Vancomycin, Metronidazole and Fidaxomycine for CDI (Days)
Figure 6-5: Daily Unit Dose of Vancomycin, Metronidazole and Fidaxomycine Orally for CDI
Figure 6-6: Vancomycin andndash; Price for Single Capsule of 250mg, 20 Capsule Supply and Full Treatment Cost vs. Oral FMT Cost (US$), September’2019
Figure 6-7: Vancomycin andndash; Price for Single Dose of 500mg and Full Treatment Cost vs. Oral FMT Cost (US$), September’2019
Figure 6-8: Metronidazole – Price for Single Dose of 500mg and Full Treatment Cost vs. Oral FMT Cost (US$), September’2019
Figure 6-9: Metronidazole – Price for Single Dose of 250mg and Full Treatment Cost vs. Oral FMT Cost (US$), September’2019
Figure 6-10: Metronidazole andndash; Price for Single Dose of 500mg/100ml IV Solution, 2400 ml Supply and Full Treatment cost vs. Oral FMT Cost (US$), September’2019
Figure 6-11: Fedaxomycin – Price for Single Dose of 200mg and Full Treatment Cost vs. Oral FMT Cost (US$), September’2019
Figure 7-1: US andndash; Fecal Microbiota Transplant Market Drivers
Figure 8-1: Challenges for US Fecal Microbiota Transplant Market
Contact:
Neeraj Chawla
neeraj@kuickresearch.com
+91-9810410366
